Josh is a Venture Partner at Forbion. He has extensive experience in building and leading companies in biotech and healthcare.
As a former CEO of Dyne, a ∼$3.5 billion Forbion portfolio company, he led the company through its initial public offering on Nasdaq in 2020, and advanced two rare muscle disease programs into clinical trials.
Prior to Dyne, he held leadership roles at several other biotechs, including Proteolix, Pharmacyclics and ZELTIQ Aesthetics, all of which were acquired by large pharmaceutical companies.
